AyuVis is a start-up biopharmaceutical company focusing on developing New Molecular Entities (NME) as immune modulating, anti-microbial, and anti-inflammatory drugs. Our pipeline of drug candidates is based on a new platform technology that modulates macrophages in the innate immune system to restore balance while fighting both infection and inflammation. Stimulating these macrophages produces a rapid therapeutic response throughout the body as we have seen in our strong preclinical data. This is unlike any existing immunotherapies today - immunotherapies which in total have annual sales of $70B. Because the antimicrobial action of our compounds is through the activation of phagocytosis, the development of multidrug resistance is not anticipated. Our goal is to save and improve lives, reduce hospital costs, & provide an effective treatment to diseases like BPD, VAP, and ARDS with no adverse side effects that are seen with the current alternatives. Our lead candidate is Orphan Drug and Rare Pediatric Disease Designated by the US FDA for the prevention of bronchopulmonary dysplasia (BPD) in at-risk preterm infants. BPD is a rare pediatric lung disease in preterm babies caused by inflammation from supplemental oxygen required for survival in the NICU and is the second leading cause of death in preterm babies. An average of 112 preterm babies die per month in the US due to the lack of an effective therapy and survivors require ongoing care. AyuVis has 2 patents approved by the USPTO and more countries which include composition of matter of our compounds, methods of use, formulations, and more.